The Time Toxicity of Cancer Treatment

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness

The ESCAPE Investigators and ESCAPE Study Coordinators* (2005) · JAMA · doi:10.1001/jama.294.13.1625 · Cited by 1,544

Balanced Crystalloids versus Saline in Noncritically Ill Adults

Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., Slovis, C. M., Lindsell, C. J., Ehrenfeld, J. M., Siew, E. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711586 · Cited by 1,170

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Lamarca, Á., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S. J., Gillmore, R., Wadsley, J., Patel, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00027-9 · Cited by 781

NXY-059 for Acute Ischemic Stroke

Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660

Physical rehabilitation for older patients hospitalized for heart failure

Kitzman, D. W., Whellan, D. J., Duncan, P., Pastva, A. M., Mentz, R. J., Reeves, G. R., Nelson, M. B., Chen, H., Upadhya, B., Reed, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026141 · Cited by 594

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309

Days Spent at Home — A Patient-Centered Goal and Outcome

Groff, A. C., Colla, C. H., & Lee, T. H.-Y. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607206 · Cited by 272

Shared decision‐making and social science: A patient perspective

Ostroff, C. L. (2024) · Colorectal Disease · doi:10.1111/codi.16857 · Cited by 2

The Time Burden of Office Visits in Contemporary Pituitary Care, 2016 to 2019

Dimitroyannis, R. C., Cyberski, T. F., Kondamuri, N. S., Polster, S. P., Das, P., Horowitz, P. M., & Roxbury, C. R. (2024) · American Journal of Rhinology and Allergy · doi:10.1177/19458924241242198 · Cited by 2

Plasma Cell-free RNA PD-L1 Expression and Overall Survival of Immune Checkpoint Inhibitor Therapy in Advanced Non-Small Cell Lung CancerPreprint

Walker, P. R., Muzaffar, M., Jayananda, S., Namireddy, P., Sharma, N., Parent, T., Cherry, C. R., & Lanman, R. B. (2022) · Preprints.org · doi:10.20944/preprints202208.0208.v1 · Cited by 2

Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer

Horimoto, Y., Jimbo, H., Ishizuka, Y., Nogami, N., Kutomi, G., & Watanabe, J. (2024) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2024-004989 · Cited by 1

Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study

Nakata, A., Hashimoto, N., Narita, Y., Wakabayashi, M., Kodama, H., Ogata, T., Honda, K., Masuishi, T., Taniguchi, H., Kadowaki, S., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae223 · Cited by 1

Time toxicity of lutetium 177 in gastroenteropancreatic neuroendocrine tumours

Bortz, M. D., Rodriguez, A. F., Luca, M. R., Waisberg, F., Enrico, D. H., Freile, B., Catani, G., Esteso, F., Musumeci, M., Vázquez, E. F., et al. (2024) · Endocrine Oncology · doi:10.1530/eo-24-0028 · Cited by 1

Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan

Yoshinami, T., Shibata, N., Tamaki, K., Ishimaru, K., Ito, S., Nukada, T., & Ohno, S. (2025) · Breast Cancer · doi:10.1007/s12282-025-01714-6 · Cited by 1

Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors

Hui, R. W., Chung, M. S. H., Li, L., Mao, X., Chiang, C., Wong, C. K. H., Wong, I. C. K., Cheung, K. S., Yuen, M., Seto, W., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101578 · Cited by 1

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway inhibitor-based regimen

Sentana‐Lledo, D., Gupta, A., Rossi, C., Burbage, S. C., Korsiak, J., Diaz, L., Wong, G. W., Pilon, D., Khilfeh, I., & Morgans, A. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1650378 · Cited by 1

Adherence of published randomised Phase 3 cancer trials to principles proposed by common-sense oncology

Abdihamid, O., Gyawali, B., Booth, C. M., Eisenhauer, E. A., Hopman, W. M., Shkabari, B., Trapani, D., Verduzco-Aguirre, H. C., Wilson, B. E., & Tannock, I. F. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116041 · Cited by 1

The importance and utility of post market drug safety monitoring in cancer therapy

Levêque, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2575099 · Cited by 1

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer

Jameson, G., Legrand, S. D., Gordon, M. S., Roe, D. J., Wertheim, B. C., Olszewski, K. L., Rabinowitz, J. D., Evans, R. M., Downes, M., Truitt, M., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103895 · Cited by 1

'Is it my last Christmas?’ Using real-world data as a prompt to reflect on goal-concordant advanced lung cancer care—a retrospective, longitudinal study

Forrest, C., Twomey, J., Qayoumi, M., Bryan, A. J., Collins, D. C., Noonan, S. A., Dennehy, K., Gaynor, S., O’Dea, P., O’Sullivan, H., et al. (2025) · BJC Reports · doi:10.1038/s44276-025-00169-8 · Cited by 1

Program Evaluation of Acupuncture and Massage Services Delivered for Symptom Management at a Community Cancer Clinic

Booher, A. G., Rico, C., Nouvini, R., Killoran, K., Drullinsky, P. R., Maxwell, S., Li, Q. S., Jutagir, D. R., McConnell, K., Godfrey, H., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00321 · Cited by 1

Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors

Rhee, C. H., Goyal, S., Liu, Y., Martini, D. J., Shabto, J. M., Nazha, B., Küçük, Ö., Carthon, B. C., Bilen, M. A., & Brown, J. T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf361 · Cited by 1

Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization

Giguère, P., Akbarian, N., Prince, C., Thavorn, K., Cieniak, C., Granger, M. W., Hamelin, L., Nampoothiri, R. V., Kennah, M., & Kekre, N. K. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70103 · Cited by 1

Time toxicity in CBCT-guided radiation therapy: A retrospective analysis of unplanned imaging burden across disease sites

Visanji, A., Li, W., Winter, J., Chung, P. W. M., & Kong, V. C. (2026) · Technical Innovations & Patient Support in Radiation Oncology · doi:10.1016/j.tipsro.2026.100379 · Cited by 1

Time toxicity in health research: a cross-sectional analysis

Serran, M. L., Zhang, D., Xiao, K., Chung, H., Leigh, J., & Chow, R. (2026) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2026-006145 · Cited by 1

Understanding financial toxicity in cancer care through a social–ecological lens

Budhu, J. A., Thom, B., & Chino, F. L. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001215 · Cited by 1

Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer

Stevens, S. X., Addo, I. Y., El-Katateny, E., Rollins, B., Lourenço, R. D. A., Booth, C. M., Shaw, J. L., & Vardy, J. L. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf111 · Cited by 1

Evaluating the environmental Effects of Simulation-Free radiation therapy for palliative treatments

Lee, J., Javor, J., Tsai, C., Cummings, B., Mesci, A., Kong, V. C., Millar, B., Dawson, L. A., Wong, R. K. S., poso-Lee, K. D., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111472 · Cited by 1

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors

McEvoy, M. T., Seashore, E. L., Cheng, W. S., Clay, S. L., Casas, J. A., & Foster, J. H. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70199 · Cited by 1

Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants

Gupta, A., Till, C., LeBlanc, M. L., Hershman, D. L., & Unger, J. M. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01182 · Cited by 1

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma

Ocio, E. M., Parmar, G., Mateos, M., Leleu, X. P., Buck, T. T., Tan, C. R., Curry, N. C., Ling, S., Quach, H., Mai, E. K., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2659263 · Cited by 2

Case Report: Proton beam therapy – friend or foe for patients with IDH-mutated WHO grade 2 and 3 gliomas?

Heggebø, L. C., Fjæra, L. F., Garrote, F. L. B., Borgen, I. M. H., Blakstad, H., Hellebust, T. P., Saxhaug, C., Knutstad, K., Rylander, H., Henry, T., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1803943 · Cited by 2

Geographic access as a modifiable determinant of cancer care: perspectives on hub-and-spoke oncology networks, travel burden and time toxicity

Fuentes, J. D. B., Aguilar, A. D. L., Okondo, E., Adeleke, S. M., Arias, A. F., Rodríguez-Lescure, Á., & Sanchez, A. D. L. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04465-8 · Cited by 1

Time Toxicity in Advanced Breast Cancer: Psychological Burden, Psychiatric Vulnerability, and Implications for Patient-Centered Decision-Making

Marano, G., Paris, I., Traversi, G., Mazza, O., Rotondaro, S., D’Angelo, T., Fuso, P., Chieffo, D. P. R., Franceschini, G., & Mazza, M. (2026) · Medicina · doi:10.3390/medicina62081551 · Cited by 1

Time toxicity in patients receiving brachytherapy and hormonal therapy for recurrent prostate cancer: a cohort study

Chow, R., Bayrakdarian, S., Zimmermann, C., Richards, G. C., Heneghan, C., Leigh, J., & Chung, H. (2026) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2026-006361 · Cited by 1

A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer

Malling, C. D., Bange, E. M., Reiner, A. S., Marcinkowski, K., Porter, S., Andronico, J., Bonenfant, K., Budrock, K., Sadowsky, H., Lee-Teh, M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29406 · Cited by 1

The Cheapest Way to Save a Patient’s Time May Be One We Will Not Pay For

Patel, V. R., & Gupta, A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29639 · Cited by 1

Brentuximab vedotin‐containing regimen time toxicity for front‐line therapy of advanced‐stage classical Hodgkin lymphoma in young adults and adults: Real‐life comparison between condensed BrECADD versus traditional Bv + AVD

Picardi, M., Vincenzi, A., & Pane, F. (2026) · British Journal of Haematology · doi:10.1111/bjh.70917 · Cited by 1

Dispensation for access to novel anticancer agents in France

Levêque, D., Beck, M., & Cotton, M. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00213-9 · Cited by 1

How we approach early phase clinical trial and off-label therapy consults in pediatric oncology: The New Agents and Innovative Therapy (NAIT) team experience

Revon‐Rivière, G., Tibout, P., Cabral, J., Siddiqi, A., Doka, A., Mills, D., Fung, K., Judd, S., Morgenstern, D. A., & Cohen‐Gogo, S. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100154 · Cited by 1

Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer

Sekar, R. R., Irani, S., Maganty, A., Montgomery, J. S., & Herrel, L. A. (2024) · Urology · doi:10.1016/j.urology.2024.05.006 · Cited by 1

All that can still be done: Communicating with precision and patient‐centeredness when recommending hospice initiation for cancer patients

Epstein, A. S. (2024) · Cancer · doi:10.1002/cncr.35558 · Cited by 1

Artificial Intelligence Algorithms in Predictive Factors for Hematologic Toxicities During Concurrent Chemoradiation for Cervical Cancer

Petre, I., Negru, S. M., Dragomir, R., Bordianu, A., Petre, I., Marc, L., & Vlad, D. C. (2024) · Cureus · doi:10.7759/cureus.70665 · Cited by 1

Clinical efficacy and safety of tegafur, gimeracil, and oteracil potassium (S-1) monotherapy for incurable oral squamous cell carcinoma patients

Sekikawa, S., Tatsumi, A., Ishikawa, S., Tanaka, S., Aiso, Y., Kikuchi, T., Suzuki, T., Ogane, S., Nomura, T., Katakura, A., et al. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.02.015 · Cited by 1

Time Toxicity: Quantifying Healthcare Utilization Attributable to Pediatric Home Ventilation

Johnson, E. D., Boss, R. D., Park, W. Y., & Aziz, K. B. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71081 · Cited by 1

Palliative management of depression in advanced cancer

Gurgenci, T., Chen, J., Jull, B., Stokes, C., Waugh, R., & Good, P. D. (2025) · Australian Journal of General Practice · doi:10.31128/ajgp-05-24-7291 · Cited by 1

“Geriatricizing” drug development – A Young International Society of Geriatric Oncology letter to the editor

Mir, N. A., Testa, G. D., & Lichtman, S. M. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.10.013 · Cited by 1

Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta‐analysis

Schiess, L. C., Song, L. L., Schädelin, S., Fürst, T., Urech, C., Friese, C. R., & Katapodi, M. C. (2026) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70076

1209 人間自動車系を考慮した灯火制御の効果評価に関する研究(情報・知能・精密機器,交通・物流)

三上, 貴., 慶祐, 森., 堀井, 泰., 和田, 隆., & 土居, 俊. (2010) · 講演論文集

How do we trade off benefits and harms of anticancer drugs for advanced cancer patients?

Kim, D. Y. (2023) · Journal of Korean Medical Association · doi:10.5124/jkma.2023.66.2.86

Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

Bojanini, L., Gupta, N. K., & Khaki, A. R. (2023) · The Oncologist · doi:10.1093/oncolo/oyad204

Scope, Findability, and Quality of Information about Music-Based Interventions in Oncology: A Review of Public-Facing Websites at NCI-Designated Cancer Centers (Preprint)Preprint

Blank, C. A., Biedka, S., Montalmant, A., Saft, K., Lape, M., Mao, K., Bradt, J., & Liou, K. T. (2023) · doi:10.2196/preprints.53440

Expanding Treatment Options for Older Adults With Prostate Cancer

Morgans, A. K. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4172

Chemotherapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Aghniya, G., & Dewi, Y. A. (2023) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/978-94-6463-280-4_46

Radiotherapy Outcomes in Adults with H3K27MAltered Midline Gliomas and Poor Performance Status

Üzel, E. K. (2024) · Comprehensive Medicine · doi:10.14744/cm.2024.02411

Illusion of control recognition may promote early palliative care engagement

Bacchi, S., Tan, S., Stretton, B., Kovoor, J. G., Gupta, A. K., McNeil, K., & Crawford, G. (2024) · Internal Medicine Journal · doi:10.1111/imj.16352

References

(2024) · Emerald Group Publishing Limited eBooks · doi:10.1108/978-1-80455-005-220241011

Digital Transformation, Equitable Access To Cancer Care, and Cancer-Related Financial Toxicity: Scoping Review (Preprint)Preprint

Sheehan, S. M., Centra, J., Dudek, K., Ashing, K. T., Beg, S., Burgener, D., Cooks, E., Cordovano, G., Dóczi, R., Gonzalez, B. D., et al. (2024) · doi:10.2196/preprints.58983

Recent Developments in Treatment of Older Patients with Breast Cancer

Landin, J., & Vetter, M. H. F. (2024) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2024.19.142

Radiotherapy recommendation, initiation, and completion: Complex questions of access and equity

Dee, E. C., Feliciano, E. J. G., Sanford, N. N., & Iyengar, P. (2024) · Cancer · doi:10.1002/cncr.35654

The current state and future direction of childcare for cancer patients: a narrative review

Yusuf, H. E., & Kumar, A. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09174-6 · Cited by 1

Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate

Stewart, C., Owen, C., Street, L. E., Hay, K. A., Perry, S., Duggan, P. R., Shafey, M., Balogh, A., Cao, J. Q., Chua, N. S., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2477725

Characteristics of professional society oncological drug evaluation in the Netherlands from 2016 to 2020: A retrospective analysis

Penninx, B. M. F., Samson, M. J., Duits, A., & Schnog, J. B. (2025) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2025.100578

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Tomlins, E., Winter, H. R., Olsson-Brown, A. C., Robinson, J., Long, S., Sheppard, S., Harnett, C., Dulloo, S., & Pickering, S. J. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.34.sup10b.s4

Quality for All: Clinical Trial Enrollment and End‐of‐Life Care in Solid and Hematologic Malignancies

Rosen, M. R., Truong, T., Gervais, C., LeBlanc, T. W., Havrilesky, L. J., & Davidson, B. A. (2025) · Cancer Medicine · doi:10.1002/cam4.70775

In Regard to Alcorn and Baldoni

Dimitroyannis, D. A. (2025) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.10.016

Bringing value to cancer research

Allen, C. J., Horn, D., Smieliauskas, F., Edge, S. B., & Greenup, R. A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1580575

Pragmatic Patient Choice-Driven Radical Treatment Approach (PRAGRAD) for Very Advanced Unresectable Oral Cavity Cancers

Sasidharan, B. K., Sidhique, S. K., Wilson, J. V., Mathew, M., Tirkey, A. J., Singh, A., Sundararaj, J. J., Thomas, H. M. T., Swathi, B., Rajendra Benny, K., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.05.088

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies

Williams, J., Tomlins, E., Winter, H. R., Olsson-Brown, A. C., Robinson, J., Long, S., Sheppard, S., Harnett, C., Dulloo, S., & Pickering, S. J. (2025) · British Journal of Nursing · doi:10.12968/bjon.2025.34.sup10b.s1

A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy

Wright, H. N., Tosteson, T. D., Hourdequin, K. C., Ripple, G. H., Fuld, A. D., Dragnev, K. H., Amin, M. A., Muralikrishnan, S., McGrath, E. B., Stannard, M. G., et al. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09784-0

Association Between Different Patterns of Opioid and Benzodiazepine Use and Risks of Emergency Department Visits and Hospitalizations: A Retrospective Cohort Study

Su, F.-Y., Tsai, M., Ng, Y., & Wu, S. (2025) · Healthcare · doi:10.3390/healthcare13162073

Patient satisfaction on prescription refill systems for breast cancer patients in Japan using a digital self-administered survey

Oshi, M., Sasamoto, M., Isoda, M., Kawashima, K., Matsubara, Y., Ide, K., Narui, K., Suganuma, N., Yamada, A., Ota, I., et al. (2025) · Breast Cancer · doi:10.1007/s12282-025-01761-z

Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer

Hosokawa, K., Ikezawa, K., Kai, Y., Takada, R., Kinomoto, T., Masumoto, T., Kawabata, M., Kishimoto, H., Kozumi, K., Urabe, M., et al. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01309-6

Addressing quality-of-life challenges for patients with end-stage metastatic castrate-resistant prostate cancer

Jang, A., Grier, A., & Barata, P. C. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf253

Oral therapies for unfit patients with acute myeloid leukemia

Petzer, V. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01074-z

Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study

Satake, T., Sasaki, M., Imaoka, H., Taro, S. K., Inoue, K., Taira, T., Igarashi, G., Amisaki, M., Takahashi, H. E., Mitsunaga, S., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100265

A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers

Hyak, J. M., Ruan, P., Jones, A. L., Verma, N., Chung, V., Grewal, U. S., Vadehra, D., Hornstein, N. J., Wang, S. C., Porembka, M. R., et al. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001283

Consequences of adverse events in cancer immunotherapy combinations – a comprehensive real-world analysis

Aanes, S. G., Nieder, C., Bates, D. W., Wiig, S., & Haukland, E. C. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2600847

From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching

Gaudio, M., Floreani, A., Schivardi, G., Alaimo, D., Basilico, V., Lorenzetti, I., Crepaldi, C., Tinterri, B., Panzardi, A., Strada, D., et al. (2025) · Tumori Journal · doi:10.1177/03008916251401048

Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer

Sedhom, R., & Dotan, E. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00980

Additional file 2 of Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics

Jávorniczky, N. R., Grishina, O., Hund, I., Pantić, M., Pfeifer, D., Schmoor, C., Thomas, J., Duyster, J., Becker, H., & Lübbert, M. (2024) · Figshare · doi:10.6084/m9.figshare.24647360

Additional file 1 of Management of pain in cancer patients— lessons from practices during the COVID-19: a qualitative study of cancer care providers’ perspectives

Cornall, G., Zhao, E., Luckett, T., Erciyas, E., Monck, D., Glare, P. A., Wang, A. Y.-Y., & Lee, Y.-C. (2024) · Figshare · doi:10.6084/m9.figshare.25271887

Additional file 1 of Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics

Jávorniczky, N. R., Grishina, O., Hund, I., Pantić, M., Pfeifer, D., Schmoor, C., Thomas, J., Duyster, J., Becker, H., & Lübbert, M. (2023) · Figshare · doi:10.6084/m9.figshare.24647152

Healthcare workload associated with transition onto kidney replacement therapy: a retrospective cohort study

Jones, C. H., Edgar, B., Thomson, P. C., Gallacher, K. I., Knight, S., Kingsmore, D., Mark, P. B., Stevenson, K., & Jani, B. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04693-0

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation

Haque, R., McGary, E. C., Yang, M. Z., Liu, R., Suga, J. M., Chen, L. H., Zhu, Z., Simmons, D. J., Hsieh, K., Cotarla, I., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2603465

Decline in Circadian Robustness in Lung Cancer Patients During Immunotherapy is Associated With Increased Risk of Disease Progression and Death

Strøm, L., Amidi, A., Wu, L. M., Meldgaard, P., Ancoli‐Israel, S., Lekander, M., Mroczek, D. K., & Zachariae, R. H. (2025) · Journal of Biological Rhythms · doi:10.1177/07487304251398276

Accounting for the Scarcity of Time as Patients Approach End of Life: The Construction of End-Weighted Time Toxicity

Jacobsen, J. C., Mahajan, S., Ekstrand, J., Hammas, K. B., May, P., & Klintman, J. (2025) · Value in Health · doi:10.1016/j.jval.2025.12.010

Hospice care for Medicaid cancer patients in Puerto Rico: implications on healthcare costs and utilization

Ortiz‐Ortiz, K. J., Vazquez-Roldan, M., Gierbolini-Bermúdez, A. J., Ramos-Fernández, M. R., Torres‐Cintrón, C. R., Pagán-Santana, Y., Suárez‐Ramos, T., & Sonawane, K. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf123

In vitro Selective Effect of Imidazole Derivatives as Inhibitors of Human Laryngeal Carcinoma

Kovalishyn, V., Rogalsky, S. P., Hodyna, D. M., Borysko, P., & Metelytsia, L. O. (2025) · Bioactivities · doi:10.47352/bioactivities.2963-654x.338

Innovations in Palliative Care Delivery in Oncology

Lam, A. B., Petrillo, L. A., El-Jawahri, A. R., Bauman, J. R., Dionne-Odom, J. N., Temel, J. S., & Nipp, R. D. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00868

Retrospective Cohort Study of Palliative Care Patterns in Advanced Pancreatic Ductal Adenocarcinoma

Mao, H., Nur, T., Armstrong, D., Ramachandran, A., Print, C. G., Nagar, S. D., Koea, J., & Srinivasa, S. (2026) · ANZ Journal of Surgery · doi:10.1111/ans.70521

Impact of 340B Exposure on Treatment Utilization and Cost for Medicare Patients With Cancer

Horn, D., & Schulman, K. A. (2026) · Health Services Research · doi:10.1111/1475-6773.70092

Reducing waiting time of injectable anticancer drug preparations in day care oncology units: A summary of evidence, implemented strategies, and perspectives for hospital pharmacists

Giraud, J.-S., Brun, M., Desmaris, R., Cottu, P. H., & Acramel, A. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261422457

The Impact of Sociodemographic Disparities on Health-Related Quality of Life for Adults with Gliomas

Perez, M. A., Riegel, D. C., & Budhu, J. A. (2026) · Cancers · doi:10.3390/cancers18050718

Disparities in adverse event perception between patients and healthcare providers in gynaecologic anticancer therapy: results from an observational web-based study in Japan

Hashimoto, H., Soejima, A., Nishimura, Y. H., Ike, A., Sugawara, M., Muneaki, S., & Abé, M. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-107743

Time Toxicity in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine Plus Cisplatin With or Without Durvalumab

Okano, N., Pirozzi, A., O’Donnell, C. D., Hayashi, M., Usón, P. L. S., Hoyek, C., Abidoye, O., Eslinger, C. R., Zheng-Lin, B., Elliott, N. M., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00126

Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice

Hawkins, L. A., Rumano, R. P., Smith, S. S., Hery, C. M. B., Fisher, J. L., Clark, A., Champion, V. L., Oppong, B. A., & Paskett, E. D. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07940-6

Use of a Delphi process to formulate a pragmatic framework for care planning in older adults with advanced bladder cancer

Kessler, E. R., Hoover, K., Coats, H., & Fischer, S. M. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10532-1

Digital Health Tools and Remote Surveillance in the Long-Term Management of Thyroid Cancer Survivors

Laskou, S., Surlin, V., Geropoulos, G., Radu, P. A., Strambu, V., Psarras, K. K., & Sapalidis, K. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1014626

Rethinking centralised oncology pharmacy practice in the era of flat-dose immunotherapy, subcutaneous formulations and visit-administration day separation: A conceptual analysis and reform proposal

Iannopollo, M. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261443223

The association between health care contact days, care experience, and out-of-pocket spending for older adult cancer survivors

Daley, N. E., Gupta, A., & Ganguli, I. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.102970

Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review

Cannella, L., Venditti, A., Palmieri, R., Puglia, S., Luppi, M., Breccia, M., & Efficace, F. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06900-w

Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care

Shrestha, S., Khanal, P., & Soto‐Pérez‐de‐Celis, E. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01151-0

Value, Access, and High-Quality Medical Oncology Care: Can We Have It All?

Tannock, I. F., Aggarwal, A. K., Verduzco-Aguirre, H. C., & Wilson, B. E. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517738

Invited Commentary: Counting What Counts in Cancer Surgery

Patel, V. R., & Gupta, A. (2026) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001985

Supporting Uptake of Mindfulness-Based Interventions for Breast Cancer Survivors: Generating Locally Relevant Estimates of Benefit

Alagiyage, K., Rodrigues, Z., Roseleur, J., Edney, L. C., Beatty, L., Johnson, C., Paterson, C. C., & Karnon, J. D. (2026) · Mindfulness · doi:10.1007/s12671-026-02860-4

Patient Out‐of‐Pocket Costs and Healthcare Utilization Related to Mastectomy vs Breast Conservation: A Claims‐Based Study

Proussaloglou, E. M., Ren, Y., Fayanju, O. M., Blitzblau, R. C., Berger, E. R., Valero, M. G., Hwang, E. S., Wheeler, S. B., & Greenup, R. A. (2026) · Journal of Surgical Oncology · doi:10.1002/jso.70281

The Toxicity of Time

Daily, K. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7907 · Cited by 19

Time Toxicity of Cancer Care—A Call to Action

Doshi, S. D., Rappaport, J. A., & Bange, E. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.47930 · Cited by 8

Time Is Money, but for Whom? The Commodification of Time Toxicity in Oncology

Gupta, A., Patel, V. R., Sedhom, R., & Booth, C. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01458

‘Time Toxicity’ in the Metastatic Setting

DiGirolamo, E. (2026) · Oncology Times · doi:10.1097/01.cot.0000000000000380

Love in the Time of Cancer

Einhorn, L. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9755 · Cited by 1